OXFORD ONCO-THERAPEUTICS
Oxford Onco-Therapeutics is a personalized medicine startup that enables oncologists to predict the right treatment for each patient's specific cancer using a data-driven approach.
OXFORD ONCO-THERAPEUTICS
Social Links:
Industry:
Artificial Intelligence Health Care Medical Software
Founded:
2021-04-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Total Employee:
1+
Status:
Active
Contact:
07517295306
Email Addresses:
[email protected]
Similar Organizations
EMMA.health
EMMA - your data driven personalised preventive healthcare coach.
SpeedCoder
Typing Practice for Programmers
More informations about "Oxford Onco-Therapeutics"
Oxford BioTherapeutics - Developing First-in-Class Cancer Therapies
Oxford BioTherapeutics pioneers next-generation antibody therapies, addressing unmet needs with OGAP®-Verify, a high-sensitivity proteomic platform identifying novel cancer targets. With …See details»
Oxford Onco-Therapeutics - Crunchbase Company Profile & Funding
Oxford Onco-Therapeutics is a personalized medicine startup that enables oncologists to predict the right treatment for each patient's specific cancer using a data-driven approach.See details»
Oxford BioTherapeutics Enters into a Strategic Collaboration with …
Oxford, UK and San Jose, California, 19th March 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug …See details»
Roche taps Oxford BioTherapeutics for cancer drug …
Mar 19, 2025 Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with Roche on the hunt for new antibody therapeutics for cancer in a deal ...See details»
Oxford BioTherapeutics Enters into a Strategic Collaboration with …
Mar 19, 2025 Oxford BioTherapeutics is a clinical stage oncology company discovering and developing first in class antibody-based therapies designed to fulfil major unmet patient needs …See details»
Oxford BioTherapeutics Enters into a Strategic Collaboration with …
Mar 26, 2025 “We are proud to partner with Roche, a global leader in oncology, to accelerate the application of novel cancer targets identified through our proprietary discovery platform, OGAP …See details»
Partnerships | Oxford BioTherapeutics
OBT entered into a strategic collaboration with Roche in March 2025 to discover novel targets for antibody-based therapeutics for the treatment of cancer. This partnership leverages our …See details»
Oxford onco-therapeutics | Bayes Centre
Sep 30, 2024 Problem Current cancer treatment resembles a one-size-fits-all approach where most patients receive similar treatments without patent stratification. We have initially focused …See details»
Roche inks cancer deal with Oxford BioTherapeutics
Mar 31, 2025 The Swiss healthcare company signs its third antibody-drug deal this year with the Oxford-based biotechnology company. Swiss multinational holding healthcare company …See details»
Licence for development of cancer treatments acquired from …
Jan 12, 2025 Boehringer Ingelheim has acquired a licence for the development of antibody-based cancer treatments from Oxford BioTherapeutics.See details»
Oxford BioTherapeutics and Roche link on antibody cancer …
Mar 20, 2025 Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment.See details»
ONCOtherapeutics
We are a strategic Contract Research Organization (CRO) running multiple clinical trials in community oncology sites throughout the US. Uniquely focused on community-based …See details»
Pipeline - Oxford BioTherapeutics
We bring 20 years of innovation to the ADC & TCE field. We have a number of partnerships and collaborations that leverage our OGAP®-Verify technology.See details»
Oxford Onco-Therapeutics - Products, Competitors, Financials, …
About Oxford Onco-Therapeutics Oxford Onco-Therapeutics operates as a personalized medicine startup in Oncology. The company uses a combination of lab-based tests and genetic …See details»
Oxford BioTherapeutics enters into a strategic collaboration with …
Mar 24, 2025 Oxford, UK and San Jose, California, 19th March 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and …See details»
Oxford onco-therapeutics | The University of Edinburgh
Problem Current cancer treatment resembles a one-size-fits-all approach where most patients receive similar treatments without patent stratification. We have initially focused on bowel …See details»
Roche teams with Oxford BioTherapeutics to develop antibody …
Mar 20, 2025 Oxford BioTherapeutics partners with Roche in a deal worth potentially over $1 billion to develop novel cancer antibody treatments.See details»
Oxford Onco-Therapeutics - Contacts, Employees, Board
Oxford Onco-Therapeutics has 1 current employee profile, Co-Founder Ashwin Nandakumar.See details»
Oxford Onco-Therapeutics - Tech Stack, Apps, Patents & Trademarks
This year, Oxford Onco-Therapeutics is projected to spend $347.6K on IT, according to Aberdeen.AI driven personalised cancer treatmentSee details»
Roche and Oxford BioTherapeutics enter oncology partnership …
Mar 21, 2025 Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based therapeutics for cancer. The multi-year …See details»